Emblica lozenges and preparation method thereof
By rationally using water-soluble and insoluble fillers in Yuganzi throat tablets, and combining the internal and external addition of sucrose and sweeteners, the gravel and sour problems of Yuganzi throat tablets are solved, improving its compliance and efficacy.
Patent Information
- Application Number
- CN202411982886.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-12-31
- Publication Date
- 2025-04-08
AI Technical Summary
The existing yuganzi throat tablets have problems of grit and astringent taste during the intake process, and it is difficult to improve their taste and compliance without increasing the preparation cost.
A new type of Yuganzi throat tablet was prepared by using water-soluble fillers and water-insoluble fillers in the core and drug-containing layer of Yuganzi throat tablets, combined with sucrose as a binder and sweetener, adding sweeteners internally, and adding solid flavors.
It effectively solves the gravel and sour problems of Yuganzi throat tablets, improves its compliance and efficacy, and ensures the improvement of the content of active ingredients and the efficacy of medicine.
Smart Images
Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
[Technical field]
[0001] The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to emblica throat lozenges and a preparation method thereof. [Background technology]
[0002] Phyllanthus emblica L. is the fruit of Phyllanthus emblica L., a plant of the Euphorbiaceae family. It is also known as oil orange, olive (Sichuan), Yunnan olive (Yunnan), green fruit, etc. It is called Amla and Phyllanthus in Tang Materia Medica. The Southern Herbal Medicine states that "the leaves are thin, like the leaves of a hollyhock, the flowers are yellow, and the food is like plums, green and yellow, with round cores with six or seven edges. It tastes bitter at first but sweet later." The Compendium of Materia Medica calls it Amla fruit, and states that "it tastes bitter at first, but becomes sweeter after a long time", so it is called Phyllanthus emblica.
[0003] The fruit of Phyllanthus emblica tastes sour and slightly astringent, clears away heat and cools blood, helps digestion and strengthens the spleen, and promotes the production of body fluids and quenches thirst. It is mainly used to treat blood heat and blood stasis, indigestion, abdominal distension, cough, sore throat, dry mouth and vitamin C deficiency. In Tibetan medicine, Phyllanthus emblica is mainly used to treat Bacon's disease, Tripa disease, blood disease, hypertension, etc. Recent research results show that the fruit of Phyllanthus emblica is rich in tannins and phenolic acid compounds, with a content of up to 45%, which can still reach 30% to 35% in immature fruits, and the tannin content in dry fruits is still 14%. Flavonoids, alkaloids, vitamins, amino acids and sugars have anti-inflammatory, antioxidant, anti-aging and liver protection effects.
[0004] Phyllanthus emblica throat lozenges are made from active ingredients extracted from Phyllanthus emblica medicinal materials and are a relatively old Chinese patent medicine variety. The Phyllanthus emblica throat lozenges currently available on the market have a distinct sour and astringent taste from the fruit, and a more obvious sense of gravel can be felt when taken orally, and the gravel and sourness are particularly obvious when taken orally to the last part. This sense of gravel comes from the various water-insoluble excipients in the tablets, especially the fillers that account for a large proportion of the tablets, which often contain a considerable amount of water-insoluble substances. If water-soluble substances are used as fillers, there will be problems with poor compressibility and easy dissolution when taken orally, so it is necessary to find an unconventional method to perfectly solve this problem. At present, there is no relevant literature or patent to optimize the taste of the existing Phyllanthus emblica throat lozenges, and it is necessary to develop a new preparation process for Phyllanthus emblica throat lozenges suitable for industrial production. [Summary of the invention]
[0005] In view of the defects of the prior art, the purpose of the present invention is to provide a kind of Phyllanthus emblica throat lozenges and a preparation method thereof, so as to solve the problems of gritty feeling and sour taste of Phyllanthus emblica throat lozenges without increasing the preparation cost and improve their compliance.
[0006] In order to achieve the above technical effects, the first aspect of the present invention is to provide a kind of Phyllanthus emblica throat lozenges, comprising a tablet core and a drug-containing layer coated on the upper and lower sides of the tablet core, wherein the tablet core comprises the following components in terms of mass percentage:
[0007] Phyllanthus emblica powder 25%~50%
[0008] Filler 41%~65%
[0009]
[0010] The drug-containing layer includes the following components according to mass percentage:
[0011]
[0012] The mass ratio of the tablet core to the drug-containing layer in the Phyllanthus emblica throat tablets is (0.6-0.8):1.
[0013] Preferably, the filler used in the tablet core is a water-soluble filler, and the filler in the drug-containing layer includes 65% to 75% of a water-soluble filler and 25% to 35% of a non-water-soluble filler; the dried emblica powder is a water-soluble sweetening substance, and 100% of a water-soluble filler is added, which solves the problem of sour and gritty taste of the emblica throat lozenges when they are taken orally to the end.
[0014] Preferably, the water-soluble filler is selected from one of sucrose, mannitol, sorbitol and lactose; the water-insoluble filler is selected from one of dextrin, maltodextrin, microcrystalline cellulose and starch.
[0015] Preferably, the binder is a 20 wt% to 25 wt% sucrose aqueous solution, which is used to fully disperse the binding particles and provide a certain degree of sweetness.
[0016] Preferably, the sweetener is selected from one of aspartame, sucralose and mogroside.
[0017] Preferably, the lubricant is selected from one or more of silicon dioxide, magnesium stearate and talc.
[0018] Preferably, the solid essence is a microencapsulated solid essence, which contains volatile components, and the volatile components are selected from one or more of menthyl acetate, isopulegol, menthone, tea polyphenols, cooling oil, and natural mint oil. The microencapsulated solid essence not only has an excellent taste-masking effect, but also can enhance the cooling effect of the Phyllanthus emblica throat tablets, making the throat of the user more comfortable.
[0019] Another aspect of the present invention is to provide a method for preparing the above-mentioned Phyllanthus emblica throat lozenges, which specifically comprises the following steps:
[0020] S1: Preparation of Phyllanthus emblica dry powder: The Phyllanthus emblica medicinal material is subjected to pulverization, vacuum extraction, filtration, concentration, drying, and pulverization in sequence to obtain the Phyllanthus emblica dry powder;
[0021] S2: Preparation of core dry granules and drug-containing layer dry granules: respectively mixing the formula amount of Phyllanthus emblica dry powder with the filler and the sweetener and performing boiling granulation to obtain core dry granules and drug-containing layer dry granules;
[0022] S3: Preparation of core mixed granules and drug-containing layer mixed granules: taking the formulated amounts of borneol, menthol, lubricant, and solid flavor respectively, adding them to the core dry granules and the drug-containing layer dry granules, and mixing them to obtain core mixed granules and drug-containing layer mixed granules respectively;
[0023] S4 tableting: firstly, the core mixed granules and the drug-containing layer mixed granules prepared in S3 are respectively pressed into a tablet core and a drug-containing layer, and then the drug-containing layers are respectively pressed on the lower two sides of the core to obtain the Phyllanthus emblica throat tablets.
[0024] Preferably, the reduced pressure extraction process in step S1 is specifically as follows: adding the crushed Emblica officinalis medicinal material into an extraction tank and soaking and extracting it with ethanol for 1 to 3 hours, during which the temperature is controlled at 42 to 50° C. and the vacuum degree is less than -0.08Mpa. After the extraction, the extract is pressurized and filtered through a 100-mesh sieve, and the filtrate is combined after extraction twice.
[0025] Preferably, in step S1, during the concentration process of the emblica extract, the vacuum degree is controlled to be less than -0.06Mpa; the drying process is spray drying, and the temperature during the process is lower than 60°C.
[0026] Preferably, the particle size of the dry paste powder obtained in step S1 is ≤0.18 mm.
[0027] Preferably, in step S2, the filler needs to be crushed before use, and the particle size after crushing is ≤0.28 mm.
[0028] Preferably, in step S2, during the boiling granulation process, the material temperature is controlled to be 35-55° C. Granulation within this temperature range can effectively retain the gallic acid content in the emblica fruit, and granulation cannot be performed at too low a temperature. In addition, the sweetener is added during the granulation process, so that the sweetener is more evenly dispersed in the granules, thereby reducing the bitterness and sourness of the emblica fruit lozenges.
[0029] Preferably, in step S2, the moisture content of the core dry granules is controlled at 3% to 6%, and the granules are sieved through a 24-mesh screen after granulation; the moisture content of the drug-containing layer dry granules is controlled at 3% to 6%, and the granules are sieved through a 14-mesh screen after granulation; the core dry granules have finer particle sizes and better taste. If the drug-containing layer dry granules are crushed too finely, more fine powder will be added, and more fine powder will adhere to the surface of the tablet, affecting the taste.
[0030] Preferably, in step S3, borneol, menthol, lubricant and solid flavor are first mixed and then crushed together, and the particle size after crushing is ≤0.18 mm, and then mixed with the core dry particles and the drug-containing layer dry particles respectively to reduce the particle size of the insoluble excipients and avoid the problem of gritty taste.
[0031] Preferably, in step S4, the tablet core pressing thickness of the Phyllanthus emblica throat lozenges is controlled at 0.12-0.14 cm, and the thickness of the single drug-containing layer is controlled at 0.06-0.08 cm.
[0032] Preferably, in step S4, the tabletting process is performed using a 12 mm shallow arc die, and the hardness of the pressed Phyllanthus emblica throat tablets is 12 to 20 kg / cm 2 , the hardness is too low and the melting is too fast; the hardness is too high, the production efficiency is low and the melting time is too long.
[0033] Compared with the prior art, the present invention has the following beneficial effects:
[0034] The invention solves the problem of the gritty taste of the Phyllanthus emblica throat lozenges by controlling the dosage of the water-soluble filler in the tablet core and the drug-containing layer respectively. Meanwhile, a certain amount of non-water-soluble filler in the drug-containing layer ensures the compressibility of the Phyllanthus emblica throat lozenges and ensures that the Phyllanthus emblica throat lozenges will not dissolve too quickly in the oral cavity.
[0035] The invention prepares the emblica dry powder by low-temperature reduced-pressure extraction, thereby greatly increasing the content of gallic acid in the emblica dry powder, and the emblica dry powder, a sweetener and an adhesive are granulated by low-temperature boiling to further reduce the loss of gallic acid in the granulation process, thereby ensuring the content of effective ingredients in the prepared emblica throat lozenges and improving the drug efficacy;
[0036] The invention uses sucrose as a binder, adds a sweetener internally and adds solid flavor externally, thereby further reducing the sourness and astringency of the Phyllanthus emblica throat lozenges and improving the compliance thereof. [Specific implementation method]
[0037] In order to make the purpose, technical scheme and advantages of the present invention more clearly understood, the present invention is described by the following specific embodiments, but is by no means limited thereto. The following are preferred embodiments of the present invention, which are only used to describe the present invention and cannot be understood as limiting the present invention. It should be pointed out that any modification, equivalent substitution and improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
[0038] The emblica dry powder in the following examples is prepared by the following process:
[0039] Preparation of emblica dry paste powder: After the emblica medicinal materials are crushed, they are added into an extraction tank and soaked in ethanol for extraction for 1-3 hours. During the process, the temperature is controlled at 42-50° C. and the vacuum degree is less than -0.08Mpa. After the extraction, the extract is pressurized and filtered out through a 100-mesh screen. After extraction twice, the filtrate is combined, and then the filtrate is concentrated under the condition of a vacuum degree of less than -0.06Mpa. After concentration, the emblica dry paste is obtained by spray drying at a temperature below 60° C., and the particle size of the emblica dry paste powder is controlled to be ≤0.18mm after crushing.
[0040] Pretreatment of auxiliary materials: fillers, sweeteners, solid flavors, borneol, menthol and lubricants are crushed separately, the particle size of fillers is ≤0.28mm, and the particle size of other auxiliary materials is ≤0.18mm.
[0041] Preparation of core dry granules: Add the prescribed amount of sucrose into purified water, stir and dissolve to prepare a binder solution with a concentration of 23%. Then, put the dried emblica powder, filler and sweetener into a one-step granulator according to the prescribed amount, spray the binder solution, and the material temperature during the granulation process should be controlled within the range of 45-60°C. After drying, sieve through a 24-mesh screen to obtain core dry granules.
[0042] Preparation of dry granules containing drug layer: Add the prescribed amount of sucrose into purified water, stir and dissolve, and prepare a binder solution with a concentration of 23%. Then, put the dry powder of Phyllanthus emblica, filler and sweetener into a one-step granulator according to the prescribed amount, spray the binder solution, and the material temperature during the granulation process should be controlled within the range of 45-60℃. After drying, granulate through a 14-mesh screen to obtain dry granules containing drug layer.
[0043] Preparation of core mixed granules and drug-containing layer mixed granules: Add borneol, menthol, mint powder flavor, magnesium stearate and silicon dioxide to the core dry granules and drug-containing layer dry granules according to the prescribed amount, mix evenly, and obtain core mixed granules and drug-containing layer mixed granules.
[0044] Tablet pressing: firstly, the tablet core mixed granules and the drug-containing layer mixed granules are pressed into a tablet core and a drug-containing layer respectively, and then the drug-containing layers are pressed on the lower two sides of the tablet core respectively to obtain the Phyllanthus emblica throat tablets.
[0045] Example 1
[0046] A kind of Phyllanthus emblica throat lozenges, comprising a tablet core and drug-containing layers coated on the upper and lower sides of the tablet core, wherein the mass ratio of the tablet core to the two drug-containing layers is 0.75:1, wherein the tablet core and the drug-containing layers respectively comprise the following components:
[0047]
[0048] Example 2
[0049] A kind of Phyllanthus emblica throat lozenge, comprising a tablet core and drug-containing layers coated on the upper and lower sides of the tablet core, wherein the mass ratio of the tablet core to the two drug-containing layers is 0.6:1, wherein the tablet core and the drug-containing layers respectively comprise the following components:
[0050]
[0051]
[0052] Example 3
[0053] A kind of Phyllanthus emblica throat lozenges, comprising a tablet core and drug-containing layers coated on the upper and lower sides of the tablet core, wherein the mass ratio of the tablet core to the two drug-containing layers is 0.8:1, wherein the tablet core and the drug-containing layers respectively comprise the following components:
[0054]
[0055] Example 4
[0056] A kind of Phyllanthus emblica throat lozenges, comprising a tablet core and drug-containing layers coated on the upper and lower sides of the tablet core, wherein the mass ratio of the tablet core to the two drug-containing layers is 0.7:1, wherein the tablet core and the drug-containing layers respectively comprise the following components:
[0057]
[0058]
[0059] Example 5
[0060] A kind of Phyllanthus emblica throat lozenges, comprising a tablet core and drug-containing layers coated on the upper and lower sides of the tablet core, wherein the mass ratio of the tablet core to the two drug-containing layers is 0.7:1, wherein the tablet core and the drug-containing layers respectively comprise the following components:
[0061]
[0062] Example 6
[0063] A kind of Phyllanthus emblica throat lozenges, comprising a tablet core and drug-containing layers coated on the upper and lower sides of the tablet core, wherein the mass ratio of the tablet core to the two drug-containing layers is 0.75:1, wherein the tablet core and the drug-containing layers respectively comprise the following components:
[0064]
[0065]
[0066] The process parameters in the above-mentioned embodiments are controlled according to the following table:
[0067] Table 1 Process parameters of Examples 1 to 6
[0068]
[0069] Comparative Examples 1-2
[0070] The preparation process of Comparative Examples 1 to 2 is the same as that of Example 1, except that the amount of each component is different, as follows:
[0071] Table 2 Composition of ingredients in Comparative Example 1 and Comparative Example 2
[0072]
[0073]
[0074] Comparative Examples 3-4
[0075] The same as Example 1, except that the process parameters during the preparation process are controlled as follows:
[0076] Table 3 Process parameters in the preparation process of Comparative Examples 3 and 4
[0077] Process parameters Comparative Example 3 Comparative Example 4 Extraction process temperature (℃) 50 70 Extraction process pressure (MPa) -0.08 -0.05 Tablet core dry granulation temperature (℃) 62～77 39～50 Moisture content of dry tablets 2.08％ 3.85％ Granulation temperature of drug-containing dry granules (℃) 63～79 40～49 Moisture content of dry granules containing drug layer 2.14％ 4.16％ Core thickness (cm) 0.12 0.12 Thickness of single drug-containing layer (cm) 0.06 0.06 <![CDATA[Hardness of Phyllanthus emblica Throat Tablets (kg / cm 2 )]]> 9.83～13.79 14.07～18.44
[0078] Comparative Example 5
[0079] The same as Example 1, except that the Phyllanthus emblica throat tablets described in this comparative example are not divided into a core tablet and a drug-containing layer, and are prepared by a one-step tableting process, and the specific process is as follows:
[0080] Pretreatment of auxiliary materials: fillers, sweeteners, solid flavors, borneol, menthol and lubricants are crushed separately, the particle size of fillers is ≤0.28mm, and the particle size of other auxiliary materials is ≤0.18mm.
[0081] 462g of emblica emblica powder, 388.5g of sucrose, 105.9g of dextrin and 7g of aspartame were respectively put into a one-step granulator, and 341.5g of 22.8% sucrose solution was sprayed into the granulator. The material temperature was controlled within the range of 39-51°C during the granulation process. After drying, the granules were sieved through a 14-mesh screen to obtain emblica emblica granules.
[0082] Then, 0.875 g of borneol, 1.75 g of menthol, 21 g of menthyl acetate, 5.25 g of magnesium stearate and 3.5 g of silicon dioxide were added to the emblica dry particles, mixed evenly, and tableted using a 12 mm shallow arc die to obtain a tablet with a hardness of 14.45 to 18.16 kg / cm 2 The tablets are made into the finished product of Phyllanthus emblica throat tablets.
[0083] Comparative Example 6
[0084] The same as Example 1, except that the emblica dry powder described in this comparative example is prepared by the following method:
[0085] Add the emblica emblica medicinal material and 6-10 times of water into an extraction tank, decoct for 1.5 hours, release the extract after decoction, filter through a 100-mesh filter screen, decoct 3 times and combine the filtrate. Then decompress and concentrate the filtrate to obtain a thick paste, dry the thick paste in a vacuum drying oven to a dry paste with a moisture content of less than 3.0%, and then use a low-temperature grinder equipped with a 0.2 mm aperture screen to grind the obtained emblica emblica dry paste powder.
[0086] Experimental Example 1: Determination of Gallic Acid Content
[0087] Take about 50mg of Phyllanthus emblica throat tablets powder, accurately weigh, place in a stoppered conical bottle, accurately add 50ml of 50% methanol, weigh, ultrasonically treat (power 200W, frequency 40kHz) for 30 minutes, cool, weigh again, make up the lost weight with 50% methanol, shake well, filter, take the filtrate as the test solution, accurately measure 10μl and inject into the liquid chromatograph. Use octadecylsilane bonded silica gel as filler, methanol-0.2% phosphoric acid solution (5:95) as mobile phase, flow rate 1.0ml / min, column temperature 35℃, detection wavelength 273nm HPLC method detection; take about 14mg of gallic acid reference substance, accurately weigh, place in a 50ml volumetric bottle, add 50% methanol to dissolve and dilute to scale, shake well, accurately measure 1ml, place in a 10ml volumetric bottle, add 50% methanol to dilute to scale, shake well as reference substance solution, and determine in the same way. The gallic acid content was calculated by peak area using the external standard method. The test results are as follows:
[0088] Table 4 Gallic acid content in dry paste powder and Phyllanthus emblica throat tablets prepared in each embodiment and each comparative example
[0089]
[0090]
[0091] Taking Example 1 as an example, the gallic acid content in the emblica dry powder is 13.10%, which accounts for 41.7% in the prescription. The theoretical content of gallic acid in the emblica throat lozenges is 5.46%, which is very close to the measured data of 5.40%. This indicates that the gallic acid content is basically not lost in the process of preparing the emblica throat lozenges from the emblica dry powder, and can be retained in large quantities. Embodiments 2 to 6 are the same as Embodiment 1.
[0092] The gallic acid content in the dry paste powder of Examples 1 to 6 is ≥13.10%, which is significantly higher than the traditional water extraction level (Comparative Example 6), and also higher than the dry paste powder prepared in Comparative Example 4 with a higher extraction temperature, indicating that low-temperature extraction of Phyllanthus emblica can retain more effective ingredients. In addition, the gallic acid content of the finished Phyllanthus emblica throat lozenges in Comparative Example 3 is significantly lower than that in the examples, and the retained samples decrease faster. It can be seen that high temperatures above 60°C will cause gallic acid degradation. Boiling granulation under relatively low temperature conditions can basically retain the gallic acid content in Phyllanthus emblica.
[0093] Experimental Example 2: Taste Evaluation of Phyllanthus Emblica Lozenges
[0094] The Phyllanthus emblica throat lozenges prepared in Examples 1 to 6 and Comparative Examples 1 to 5 were subjected to oral test.
[0095] 20 healthy volunteers aged over 18 were selected as group A (10 males and 10 females), and 20 volunteers aged over 18 with throat discomfort were selected as group B (10 males and 10 females), and the taste of the samples of Phyllanthus emblica throat tablets prepared in Examples 1 to 6 and Comparative Examples 1 to 5 were compared. Before tasting, rinse the mouth with water 3 times, each time the sample was kept on the tongue for more than 1 minute, and the interval between two tastings was more than 20 minutes. The order of tasting the samples was randomly disrupted, and the tasters were asked to evaluate the taste according to the table below.
[0096] Table 5 Taste evaluation scoring criteria
[0097]
[0098] The taste test results are as follows (the closer the total score is to 0, the more moderate the taste)
[0099] Table 6 Taste test results of Phyllanthus emblica throat lozenges prepared in various embodiments and comparative examples
[0100]
[0101] As can be seen from the above table, Examples 1 to 6 have obvious taste masking effects, and the test subjects basically do not feel the grittiness, sourness, and bitterness, while Comparative Examples 1, 2, and 5 all have varying degrees of discomfort.
[0102] Although the embodiments of the present invention have been disclosed above, they are not limited to the applications listed in this specification and implementation. They can be applied to various fields suitable for the present invention. For those familiar with the art, other modifications can be easily realized. Therefore, without departing from the general concept defined by the claims and equivalent scope, the present invention is not limited to the specific details listed. The above description is only a preferred embodiment of the present application and an explanation of the technical principles used.
[0103] Those skilled in the art should understand that the scope of the invention involved in this application is not limited to the technical solutions formed by a specific combination of the above-mentioned technical features, but should also cover other technical solutions formed by any combination of the above-mentioned technical features or their equivalent features without departing from the inventive concept.
Claims
1. A kind of Phyllanthus emblica throat lozenge, characterized in that: It includes a tablet core and a drug-containing layer coated on the upper and lower sides of the tablet core, wherein the tablet core includes the following components in terms of mass percentage: The drug-containing layer includes the following components according to mass percentage: The mass ratio of the tablet core to the drug-containing layer in the Phyllanthus emblica throat tablets is (0.6-0.8):
1.
2. The emblica lozenge according to claim 1, characterized in that: The filler used in the tablet core is a water-soluble filler, and the filler in the drug-containing layer includes 65% to 75% of a water-soluble filler and 25% to 35% of a water-insoluble filler.
3. The emblica lozenge according to claim 2, characterized in that: The water-soluble filler is selected from one of sucrose, mannitol, sorbitol and lactose; the water-insoluble filler is selected from one of dextrin, maltodextrin, microcrystalline cellulose and starch.
4. The Phyllanthus emblica throat lozenge according to claim 1, characterized in that: The binder is a 20wt% to 25wt% sucrose aqueous solution; the sweetener is selected from one of aspartame, sucralose, and mogroside; the lubricant is selected from one or more of silicon dioxide, magnesium stearate, and talc; the solid flavor is a microencapsulated solid flavor, selected from one or more of menthyl acetate, isopulegol, menthone, tea polyphenols, cooling oil, and natural mint oil.
5. The method for preparing the Phyllanthus emblica throat lozenges according to any one of claims 1 to 4, characterized in that: The steps include: S1: Preparation of Phyllanthus emblica dry powder: The Phyllanthus emblica medicinal material is subjected to pulverization, vacuum extraction, filtration, concentration, drying, and pulverization in sequence to obtain the Phyllanthus emblica dry powder; S2: Preparation of core dry granules and drug-containing layer dry granules: respectively mixing the formula amount of Phyllanthus emblica dry powder with the filler and the sweetener and performing boiling granulation to obtain core dry granules and drug-containing layer dry granules; S3: Preparation of core mixed granules and drug-containing layer mixed granules: taking the formulated amounts of borneol, menthol, lubricant, and solid flavor respectively, adding them to the core dry granules and drug-containing layer dry granules prepared in step S2, and mixing them to obtain core mixed granules and drug-containing layer mixed granules respectively; S4 tableting: firstly, the core mixed granules and the drug-containing layer mixed granules prepared in S3 are respectively pressed into a tablet core and a drug-containing layer, and then the drug-containing layers are respectively pressed on the lower two sides of the core to obtain the Phyllanthus emblica throat tablets.
6. The method for preparing the Phyllanthus emblica lozenges according to claim 5, characterized in that: The reduced pressure extraction process described in step S1 is specifically as follows: adding the crushed Phyllanthus emblica medicinal material into an extraction tank and soaking and extracting it with ethanol for 1 to 3 hours, during which the temperature is controlled at 42 to 50° C. and the vacuum degree is less than -0.08Mpa. After the extraction, the extract is pressurized and filtered through a 100-mesh sieve. After extraction twice, the filtrate is combined.
7. The method for preparing the Phyllanthus emblica lozenges according to claim 8, characterized in that: In step S1, during the concentration process of the emblica extract, the vacuum degree is controlled to be less than -0.06Mpa; the drying process is spray drying, and the temperature during the process is lower than 60°C.
8. The method for preparing the Phyllanthus emblica lozenges according to claim 5, characterized in that: The particle size of the dry paste powder obtained in step S1 is ≤0.18 mm; in step S2, the filler needs to be crushed before use, and the particle size after crushing is ≤0.28 mm.
9. The method for preparing the Phyllanthus emblica lozenges according to claim 5, characterized in that: In step S2, during the boiling granulation process, the material temperature is controlled to be 35-55°C.
10. The method for preparing the Phyllanthus emblica lozenges according to claim 5, characterized in that: In step S4, the tabletting process is to use a 12mm shallow arc die to perform tabletting, and the hardness of the pressed Phyllanthus emblica throat tablets is 12-20kg / cm 2 The tablet core pressing thickness is controlled at 0.12-0.14 cm, and the thickness of the single drug-containing layer is controlled at 0.06-0.08 cm.